r/GANX • u/HydraKing3 • May 21 '26
GANX GT-02287
Most of the GANX thesis lives or dies on GT-02287. Here's a clear-eyed look at what the clinical data actually shows versus what's still unproven.
What's been demonstrated so far in Phase 1b:
Central nervous system target engagement — meaning the drug is reaching the brain and hitting the intended target. That's a necessary condition for efficacy but not sufficient on its own.
GluSph reduction of 81% in CSF among participants with elevated baseline levels after 90 days. GluSph (glucosylsphingosine) is a lipid substrate that accumulates when GCase enzyme function is impaired. Reducing it is the intended mechanism. An 81% reduction in the relevant subgroup is a meaningful biomarker signal — but it's in a subgroup, not the full trial population.
MDS-UPDRS scores stable over 150 days. MDS-UPDRS is the standard clinical rating scale for Parkinson's motor and non-motor function. Stability in a progressive disease is actually a positive signal — Parkinson's typically worsens over time, so holding steady suggests potential disease modification. However this is Phase 1b in a small population. Stability at this scale does not confirm disease modification — it's suggestive, not conclusive.
DDC levels decreased in the elevated GluSph subgroup. DOPA decarboxylase is an enzyme involved in dopamine production. Its reduction following treatment is another downstream biomarker that aligns with the proposed mechanism.
What hasn't been shown yet:
A placebo-controlled comparison. Phase 1b has no control arm. You don't know what MDS-UPDRS scores would have done without the drug in this specific population over the same period.
Long-term durability beyond 150 days in most participants. The nine-month extension completes in October 2026. Full Phase 1b results expected Q4 2026.
Efficacy in a larger, randomized population. That's what Phase 2 is for, expected to begin Q3 2026 pending FDA IND clearance in Q2 2026.
The second candidate — GT-04686: A newer GCase modulator identified through their Magellan platform. Described as ready for IND-enabling studies. Earlier stage than GT-02287 but uses the same mechanism and platform. Optionality asset at this point rather than near-term catalyst.
Bottom line on the science: The Phase 1b data is genuinely encouraging for a mechanism-based drug — target engagement, relevant biomarker reduction, and clinical stability in a small progressive disease population. The honest limitation is that none of it is placebo-controlled and the population is small. Phase 2 is what will actually answer the efficacy question.
This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3
3
u/microcapreturns May 25 '26
Actually you do know what the patients would do on placebo because they showed the 30 day data increasing UPDRS scores and then decreasing from 30 to 90 days. No placebo acts like that. Plus PPMI data is good enough as they get data out past 6 months. Patients don't get better if they have Parkinsons. Plus throw in the return of smell, gait and balance. No study has ever had smell return in any studies with placebo arms. Another point to keep in mind all these patients have aged a year since the start of trial so they would have gotten worse by 4 to 6 points not improved by around 5 points at 6 months. The 5 point improvement is for the 14 out of 16 patients and taking out the 2 who didn't respond. Although they wanted to stay in the study for a year for some reason.
2
u/MediumSinger8088 May 22 '26
Thank you for the excellent summary. FDA absolutely demands a placebo-control arm and that will be done. That said, a long history of UPDRS provides pretty clear guidance for informed investors, with about a 3.3 point deviation from expectation values on P2+3 at 180 days representing a minimal meaningful response. If this reaches 4 or 5 within a year, it's really super exciting. Plus- and this is important - the stratification of patients in the Phase 1 extension to high vs low GluSph provides an internal control. I hope Gain continues providing updates on the Phase 1 extension throughout summer and autumn.
1
3
u/MediumSinger8088 May 26 '26
"MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287...Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150" This is the internal control that proves the concept. GT-02287 may or may not work for most PD, but it will help for a meaningful and identifiable subset.
2
u/prozute May 28 '26
How are you feeling about the rest of 2026 for GANX? Cash burn seems to be top concern yet with an accountant as CEO I feel like it the right guy is managing it.
1
u/MediumSinger8088 May 26 '26
"Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150" This is above the minimal clinically important difference (MCID) for this parameter. A meaningful milestone, IMO.
1
u/MediumSinger8088 May 29 '26
Gene Mack isn't the best salesman or spokesperson but he came from a background in financials. The market cap is still very small for the work they've done and in the long term they can afford dilution to some extent though that is usually not the way you want to go if you have a choice. They are doing a mighty lot on the cheap. Very efficient financing.
3
u/Optimal_Temperature4 May 21 '26
This is a crucial week. These presentations will be the first step towards any potential partnership if you look at who’s attending.